- US-listed companies
- BeOne Medicines Ltd.
- Income statement
BeOne Medicines Ltd.ONC
Market cap
$443.5B
P/E ratio
| 2016/12 | 2017/12 | 2018/12 | 2019/12 | 2020/12 | 2021/12 | 2022/12 | 2023/12 | 2024/12 | |
| Revenue | 1 | 238 | 198 | 428 | 309 | 1,176 | 1,416 | 2,500 | 3,800 |
| Revenue growth (%) | - | ||||||||
| Cost of revenue | - | 5 | 29 | 71 | 71 | 165 | 286 | - | - |
| Gross profit | - | - | - | - | - | - | - | 2,079 | 3,216 |
| Gross margin (%) | - | - | - | - | - | - | - | ||
| Research & development | 98 | 269 | 679 | 927 | 1,295 | 1,459 | 1,641 | 1,779 | 1,953 |
| Selling, general & administrative | - | 63 | 195 | 388 | 600 | 990 | 1,278 | 1,505 | 1,831 |
| Operating margin (%) | |||||||||
| Operating income | -117 | -98 | -706 | -960 | -1,658 | -1,439 | -1,790 | -1,208 | -568 |
| Operating expenses | 118 | 337 | 904 | 1,388 | 1,967 | 2,615 | 3,206 | 3,287 | 3,784 |
| Income before tax | -119 | -91 | -690 | -944 | -1,618 | -1,439 | -1,961 | -826 | -533 |
| Pretax margin (%) | -11,136.7 | -38.2 | -348 | -220.4 | -523.9 | -122.3 | -138.5 | -33 | -14 |
| Provision for income taxes | 0 | 2 | -16 | 7 | -18 | -25 | 43 | 56 | 112 |
| Effective tax rate (%) | |||||||||
| Net income | -119 | -93 | -674 | -949 | -1,597 | -1,413 | -2,004 | -882 | -645 |
| Net income margin (%) | |||||||||
| Earnings per share | - | - | - | - | - | -1.17 | -1.49 | -0.65 | -0.47 |
| Diluted EPS | - | - | - | - | - | -1.17 | -1.49 | -0.65 | -0.47 |
| EBITDA | - | ||||||||
| EBITDA margin (%) | - |